Trial results

Semaglutide in Treatment of Obesity

NCT06604624 on ClinicalTrials.gov · last registry update 2026-04-06

Finished 27 August 2025, after enrolling 462 people. Primary outcome, as filed: Relative percentage change in body weight from baseline at 44 weeks of treatment. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

462

Started

2024-09-20

Primary completion

2025-08-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative percentage change in body weight from baseline at 44 weeks of treatment

Conditions studied

Weight Management

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.